Santen Pharmaceutical Sustainability Profile
Santen Pharmaceutical Co., Ltd., commonly known as Santen, is a leading global ophthalmic pharmaceutical company headquartered in Japan. Established in 1890, Santen has a rich history of innovation in the eye care industry, focusing on the development and marketing of prescription pharmaceuticals and medical devices. With a strong presence in major operational regions including Europe, North America, and Asia, Santen is dedicated to improving the quality of life for patients with eye diseases. The company’s core product offerings include treatments for glaucoma, dry eye, and retinal diseases, distinguished by their commitment to research and development. Santen's unique approach combines advanced technology with a deep understanding of patient needs, positioning it as a trusted leader in ophthalmology. Notable achievements include a robust pipeline of innovative therapies and a strong market presence, underscoring Santen's dedication to advancing eye health globally.
DitchCarbon Score
How does Santen Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Santen Pharmaceutical's score of 41 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Santen Pharmaceutical's reported carbon emissions
In 2023, Santen Pharmaceutical Co., Ltd., headquartered in Japan, reported significant carbon emissions, with total Scope 3 emissions amounting to approximately 196,579,000 kg CO2e. The breakdown of these emissions includes capital goods (about 87,182,000 kg CO2e), purchased goods and services (approximately 102,440,000 kg CO2e), and other categories such as business travel and employee commute. Santen has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 50% by FY 2030 from a FY 2019 baseline. This includes a specific target to reduce Scope 1 emissions by 30% from 2020 levels by 2030, with an interim goal of achieving near-zero emissions for both Scope 1 and Scope 2 by the mid-2020s. Additionally, the company aims to cut Scope 3 emissions from purchased goods and services by 15% within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and reflect Santen's commitment to addressing climate change within the pharmaceutical sector. The company is actively working towards these goals, demonstrating a proactive approach to sustainability and carbon footprint reduction.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | 00,000,000 |
| Scope 2 | - | - | - | - | 0,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 |
How Carbon Intensive is Santen Pharmaceutical's Industry?
How Carbon Intensive is Santen Pharmaceutical's Location?
Santen Pharmaceutical's Scope 3 Categories Breakdown
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 80% of Scope 3 emissions.
Top Scope 3 Categories
Santen Pharmaceutical's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Santen Pharmaceutical has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Santen Pharmaceutical's sustainability data and climate commitments